A5026770999- Sarcoma Diagnosis and Treatment
- Cancer Immunotherapy and Biomarkers
- Bone Tumor Diagnosis and Treatments
- Lung Cancer Treatments and Mutations
- Histone Deacetylase Inhibitors Research
- Gastrointestinal Tumor Research and Treatment
- Musculoskeletal synovial abnormalities and treatments
- CAR-T cell therapy research
- Peptidase Inhibition and Analysis
- Medical Imaging Techniques and Applications
- Oral and Maxillofacial Pathology
- Medical Imaging and Pathology Studies
- Gastric Cancer Management and Outcomes
- Soft tissue tumor case studies
- Neurofibromatosis and Schwannoma Cases
- Cancer Diagnosis and Treatment
- Vascular Tumors and Angiosarcomas
- Colorectal Cancer Treatments and Studies
- Bone and Joint Diseases
- Immune cells in cancer
- Advanced X-ray and CT Imaging
- Lymphoma Diagnosis and Treatment
- Radiomics and Machine Learning in Medical Imaging
- Cancer, Stress, Anesthesia, and Immune Response
- Tryptophan and brain disorders
Kyungpook National University Hospital
2025
Memorial Sloan Kettering Cancer Center
2015-2024
Samsung Medical Center
2023
Laboratoire des Sciences de l'Ingénieur, de l'Informatique et de l'Imagerie
2021
Memorial Hospital
2020
Ohio University
2020
Cornell University
2007-2019
Brigham and Women's Hospital
2014
The Ohio State University
2014
Nationwide Children's Hospital
2014
<h3>Importance</h3> Patients with advanced sarcoma have limited treatment options. Talimogene laherparepvec (T-VEC) has been shown to increase tumor-specific immune activation via augmenting antigen presentation and T-cell priming. <h3>Objective</h3> To examine whether T-VEC in combination pembrolizumab is associated increased tumor-infiltrating lymphocyte infiltration programmed death-ligand 1 expression thus antitumor activity patients locally or metastatic sarcoma. <h3>Design, Setting,...
Abstract Purpose: Epacadostat, an indole 2,3 dioxygenase 1 (IDO1) inhibitor, proposed to shift the tumor microenvironment toward immune-stimulated state, showed early promise in melanoma but has not been studied sarcoma. This study combined epacadostat with pembrolizumab, which modest activity select sarcoma subtypes. Patients and Methods: phase II enrolled patients advanced into five cohorts including (i) undifferentiated pleomorphic (UPS)/myxofibrosarcoma, (ii) liposarcoma (LPS), (iii)...
The purpose of this study is to determine the overall proportion clinically worrisome and benign pneumatosis intestinalis (PI) occurring in patients with cancer evaluate associated risk factors CT features.We retrospectively studied examinations 84 treated at our tertiary center. Reviewers who were blinded clinical data classification analyzed PI terms location, pattern (linear, cystic, or both), features, including pneumoperitoneum, portomesenteric venous air, bowel wall thickening,...
Abstract PD-1 blockade (nivolumab) efficacy remains modest for metastatic sarcoma. In this paper, we present an open-label, non-randomized, non-comparative pilot study of bempegaldesleukin, a CD122-preferential interleukin-2 pathway agonist, with nivolumab in refractory sarcoma at Memorial Sloan Kettering/MD Anderson Cancer Centers (NCT03282344). We report on the primary outcome objective response rate (ORR) and secondary endpoints toxicity, clinical benefit, progression-free survival,...
The combination of pexidartinib and binimetinib was safe tolerable demonstrated encouraging signs efficacy in two patients with advanced gastrointestinal stromal tumor (GIST) refractory to tyrosine kinase inhibitors (TKIs).Molecular profiling GISTs at diagnosis upon progression may provide insight into the mechanisms response or resistance targeted therapies.Additional trials are needed further explore combined KIT MEK inhibition treatment-naïve TKI-refractory GIST.Nearly all develop...
Dual targeting of the gastrointestinal stromal tumor (GIST) lineage-specific master regulators, ETV1 and KIT, by MEK KIT inhibitors were synergistic preclinically may enhance clinical efficacy. This trial was designed to test efficacy safety imatinib plus binimetinib in first-line treatment GIST.
Percutaneous CT-Guided Bone Biopsy: Diagnosis of Malignancy in Lesions With Initially Indeterminate Biopsy Results and CT Features Associated Diagnostic or ResultsSinchun Hwang1, Robert A. Lefkowitz1, Jonathan Landa1, Junting Zheng2, Chaya S. Moskowitz2, Majid Maybody1, Meera Hameed3 David M. Panicek1Audio Available | Share
Aims Histones are essential components of chromatin, and mutations in histones lead to alterations methylation acetylation, which play an important role tumorigenesis. Most the chondroblastomas harbour H3K36M mutation. With availability a mutation‐specific antibody, we sought assess sensitivity this antibody histone series chondroblastoma cases. Methods results Immunohistochemical staining with antibodies against H3K36M, trimethylated (H3K27me3 H3K36me3) osteoblastic marker ( SATB 2) was...